Susceptibility to adverse drug reactions

Research output: Contribution to journalArticlepeer-review

Authors

  • Robin Ferner
  • Jeffrey Aronson

Colleges, School and Institutes

External organisations

  • Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK.

Abstract

The pharmacological effects of a drug depend on its concentration at the site of action, and therefore on the concentration in blood and on the dose. The relationship between the concentration or dose and the corresponding effect can usually be represented mathematically as a rectangular hyperbola; when effect is plotted against log concentration or log dose, the curve is sigmoidal.

Inevitably, the effect size and the doses causing benefit and harm will differ among individuals, since they are biological phenomena: some individuals are more likely than others to suffer harm at any given dose. Some harmful effects can occur at much lower doses than those used in therapeutics; that is, the log dose–response curve for harm lies far to the left of the log dose–response curve for benefit. Those who suffer such reactions are hypersusceptible. When the dose–response curves for harm and therapeutic effect are in the same range, dose cannot separate the harmful effects from the therapeutic effects, and adverse reactions are collateral. Toxic effects occur when harmful doses are above the doses needed for benefit.

In this review we consider factors that influence a subject's susceptibility to adverse drug reactions. Determinants of susceptibility include Immunological, Genetic, demographic (Age and Sex), Physiological and Exogenous factors (drug–drug interactions, for example), and Diseases and disorders such as renal failure, giving the mnemonic I GASPED. Some susceptibility factors are discrete (for example, all‐or‐none) and some are continuous; susceptibility can therefore be discrete or continuous; and the factors can interact to determine a person's overall susceptibility to harm.

Citing Literature

Bibliographic note

© 2019 The British Pharmacological Society.

Details

Original languageEnglish
Pages (from-to)2205-2212
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume85
Issue number10
Early online date6 Jun 2019
Publication statusPublished - 1 Oct 2019

Keywords

  • genetic polymorphisms, prescribing, adverse drug reactions, pharmacodynamics, pharmacokinetics